Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

141.25
-2.2200-1.55%
Post-market: 140.82-0.4299-0.30%18:03 EDT
Volume:1.24M
Turnover:175.17M
Market Cap:14.41B
PE:20.70
High:143.02
Open:142.88
Low:140.34
Close:143.47
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.77
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.90
PE(LYR):30.25

Loading ...

Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says

MT Newswires Live
·
Jul 01

Neurocrine (NBIX) Receives a Buy from Jefferies

TIPRANKS
·
Jun 30

Neurocrine price target raised to $208 from $182 at UBS

TIPRANKS
·
Jun 30

Neurocrine Biosciences, Inc : Jefferies Raises Target Price to $200 from $181

THOMSON REUTERS
·
Jun 29

What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders

Simply Wall St.
·
Jun 22

Deutsche Bank Raises Neurocrine Biosciences Price Target to $170 From $155, Maintains Hold Rating

MT Newswires Live
·
Jun 22

Neurocrine Biosciences, Inc. : Deutsche Bank Raises Target Price to $170 From $155

THOMSON REUTERS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors

TIPRANKS
·
Jun 18

Neurocrine presents first retrospective case series of Crenessity

TIPRANKS
·
Jun 16

Neurocrine presents two-year Crenessity data

TIPRANKS
·
Jun 15

Neurocrine reports 2-year Phase 3 CAHtalyst Adult data showing cardiometabolic gains with CRENESSITY in classic CAH

Reuters
·
Jun 15

Vir Biotechnology names Timothy Coughlin to board, taps him as audit committee chair

Reuters
·
Jun 11

Neurocrine Biosciences director Stephen A. Sherwin disposes of USD 4.12 million in common shares

Reuters
·
Jun 10

Neurocrine director Leslie V Norwalk disposes of USD 210,071.63 in common shares

Reuters
·
Jun 09

Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug

MT Newswires Live
·
Jun 09

Neurocrine reports new post-hoc data from KINECT 4 trial

TIPRANKS
·
Jun 09

Neurocrine says post-hoc KINECT 4 data show 94% response or remission with Ingrezza in tardive dyskinesia

Reuters
·
Jun 09

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of Ingrezza® (Valbenazine) Capsules Across a Broad Range of Patients

THOMSON REUTERS
·
Jun 09

Neurocrine presents new data showing Improvements with INGREZZA

TIPRANKS
·
Jun 08